<DOC>
	<DOC>NCT01611688</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to describe the safety and tolerability of single intravenous (i.v.) and subcutaneous (s.c.) doses of NNC0215-0384 in subjects with active rheumatoid arthritis (RA) on background methotrexate (MTX) treatment.</brief_summary>
	<brief_title>First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<criteria>Active RA, characterised by a DAS28 (CRP)(Disease Activity Score based on 28 joints and CRP) above 3.2 and a minimum of two swollen joints based on a 68/66 joint count at screening Concomitant treatment with MTX (7.5 25 mg/week both inclusive) for at least 16 weeks, with a stable dose for at least 6 weeks prior to dosing Subjects with chronic inflammatory autoimmune disease other than RA History of or current inflammatory joint disease other than RA such as gout (crystal proven), psoriatic arthritis, juvenile idiopathic arthritis, current reactive arthritis or Lyme disease Any active or ongoing chronic infectious disease (e.g. chronic osteomyelitis, chronic pyelonephritis) requiring systemic antiinfectious treatment within 4 weeks prior to randomisation Clinically significant cardiac or cardiovascular disease Past or current malignancy Latent or active tuberculosis (TB) as documented by: A positive QuantiFeronÂ® test (test can be performed up to 2 months prior to dosing). One retest is allowed in case of inconclusive results. A history of active TB within the last 3 years even, if treated effectively. A history of active TB more than 3 years ago, if there is no documentation that the prior antiTB treatment was appropriate in duration and type</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>